A safety evaluation of evolocumab

Alirocumab for the treatment of hypercholesterolemia

(2017) Brian Tomlinson et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

(2017) John J.P. Kastelein et al.   Journal of Clinical Lipidology

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab

(2017) Jennifer G. Robinson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cognitive Function in a Randomized Trial of Evolocumab

(2017) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials

(2017) Alberico L. Catapano et al.   Scientific Reports

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

(2016) Eli M. Roth et al.   ATHEROSCLEROSIS

Reductions in Atherogenic Lipids and Major Cardiovascular EventsClinical Perspective

(2016) Kausik K. Ray et al.   CIRCULATION

Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome

(2016) Dirk J. Blom et al.   DIABETES OBESITY & METABOLISM

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Familial hypercholesterolaemia: A global call to arms

(2015) Antonio J. Vallejo-Vaz et al.   ATHEROSCLEROSIS

Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance

(2015) Dirk J. Blom et al.   CIRCULATION RESEARCH

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

(2015) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

(2014) Dirk J. Blom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia

(2013) Michael J. Koren et al.   CIRCULATION

Stratification of Antibody-Positive Subjects by Antibody Level Reveals an Impact of Immunogenicity on Pharmacokinetics

(2012) Lei Zhou et al.   AAPS Journal

Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29 365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants

(2012) Roeland Huijgen et al.   EUROPEAN HEART JOURNAL

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

(2012) Paul M Ridker et al.   LANCET